65,437 trials
Keratoconjunctivitis Sicca
Primary: Inferior Corneal Fluorescein Staining — 2.40; 2.07; 2.11 units on a scale
Social Anxiety in Autistic Adults
Primary: Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2 — 34.3; 55.5; 64.0 score on a scale
Asthma
Primary: Percentage of Participants With Asthma Exacerbations at Week 12 — 38.9; 25.0; 41.7; 38.9 percentage of participants — p=0.312
Healthy
Primary: AUC — 4.78; 15.00; 5.41; 16.34 uM hr/L
Smallpox
Primary: ELISA GMT — 875.1; 1099.6 Titer
Orofacial Swelling
Primary: Pain Measurement as Assessed on a Heft-Parker 170 mm Visual Analog Scale — 69.3; 59.2 units on a scale
Nonalcoholic Steatohepatitis (NASH)
Primary: Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor — 1236.0; 2450.6; 7712.1; 12458.8 hours*nanogram/millilitre (h*ng/mL)
Dysfunctional Tear Syndrome
Primary: Negative and Positive Agreement of the InflammaDry at Diagnosis of Dry Eyes — 81; 98; 86; 97 percentage of cases
Fibromyalgia
Primary: Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE) — 8; 16; 0; 3 Participants
Cardiovascular Disease
Primary: Change in Pulse Wave Velocity (PWV) — -0.25; -0.16 m/s
Horizontal Ridge Deficiency
Primary: Change From Baseline in Radiological Bone Width Augmentation at 0 mm — 2.274 mm
History of Myocardial Infarction · Hypertriglyceridemia
Primary: Mean Adherence Rate at the End of the Study (Visit 3) — 0.37 proportion of days
Multiple Myeloma
Primary: Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis — 100; 53.3; 46.7; 100 percentage of participants
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants
Obesity
Primary: Rate of MOVE! Visits Per 1000 Candidate Veterans — 4.504; 4.853; 4.824; 5.061 Rate of MOVE! Visits per 1000 Candidate — p=.011